Quick Read Eli Lilly (LLY) dropped 8% last month despite 48% revenue growth, leaving Citi's $1,600 Street-high target implying 45% upside. Novo Nordisk (NVO) offers only ~10% analyst upside and Merck (MRK) just ~6%, making Lilly the clear outlier for implied returns across pharma peers. Retatrutide showed bariatric-surgery-level weight loss in trials, with a BLA filing planned for Q1 2027 and oral GLP-1 Foundeo jumping from 8,000 to 36,000 prescribers in one quarter. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.